These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 31432248)
21. Tumor Budding in Intrahepatic Cholangiocarcinoma: A Predictor of Postsurgery Outcomes. Tanaka M; Yamauchi N; Ushiku T; Shibahara J; Hayashi A; Misumi K; Yasunaga Y; Morikawa T; Kokudo T; Arita J; Sakamoto Y; Hasegawa K; Fukayama M Am J Surg Pathol; 2019 Sep; 43(9):1180-1190. PubMed ID: 31335353 [TBL] [Abstract][Full Text] [Related]
22. TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels. Surrey LF; Frank R; Zhang PJ; Furth EE Am J Surg Pathol; 2014 Feb; 38(2):224-7. PubMed ID: 24418856 [TBL] [Abstract][Full Text] [Related]
23. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Huss JM; Torra IP; Staels B; Giguère V; Kelly DP Mol Cell Biol; 2004 Oct; 24(20):9079-91. PubMed ID: 15456881 [TBL] [Abstract][Full Text] [Related]
24. CD10+ fibroblasts are more involved in the progression of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma. Nishihara Y; Aishima S; Hayashi A; Iguchi T; Fujita N; Taketomi A; Honda H; Tsuneyoshi M Histopathology; 2009 Oct; 55(4):423-31. PubMed ID: 19817893 [TBL] [Abstract][Full Text] [Related]
25. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078 [TBL] [Abstract][Full Text] [Related]
26. Laparoscopic hepatopancreaticoduodenectomy for synchronous gallbladder cancer and extrahepatic cholangiocarcinoma: a case report. Yao GL World J Surg Oncol; 2022 Jun; 20(1):190. PubMed ID: 35681223 [TBL] [Abstract][Full Text] [Related]
27. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Tran Cao HS; Zhang Q; Sada YH; Chai C; Curley SA; Massarweh NN Cancer; 2018 Jan; 124(1):74-83. PubMed ID: 28841223 [TBL] [Abstract][Full Text] [Related]
28. Synchronous carcinoma of the gallbladder in a patient with intrahepatic bile duct carcinoma. Taniai N; Onda M; Tajiri T; Yoshida H; Naitou Z Hepatogastroenterology; 2000; 47(31):121-4. PubMed ID: 10690592 [TBL] [Abstract][Full Text] [Related]
29. DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological data. Goeppert B; Roessler S; Becker N; Zucknick M; Vogel MN; Warth A; Pathil-Warth A; Mehrabi A; Schirmacher P; Mollenhauer J; Renner M Histopathology; 2017 Jun; 70(7):1064-1071. PubMed ID: 28130841 [TBL] [Abstract][Full Text] [Related]
30. Cell of origin in biliary tract cancers and clinical implications. Moeini A; Haber PK; Sia D JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585 [TBL] [Abstract][Full Text] [Related]
32. CRABP2 and FABP5 expression levels in diseased and normal pancreas. Hughes CS; ChinAleong JA; Kocher HM Ann Diagn Pathol; 2020 Aug; 47():151557. PubMed ID: 32593808 [TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. Aishima S; Oda Y J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):94-100. PubMed ID: 25181580 [TBL] [Abstract][Full Text] [Related]
34. Clinical diagnosis and staging of cholangiocarcinoma. Blechacz B; Komuta M; Roskams T; Gores GJ Nat Rev Gastroenterol Hepatol; 2011 Aug; 8(9):512-22. PubMed ID: 21808282 [TBL] [Abstract][Full Text] [Related]
35. Biliary tract cancer. Curley SA Cancer Treat Res; 1997; 90():273-307. PubMed ID: 9367089 [No Abstract] [Full Text] [Related]
36. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives. Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541 [TBL] [Abstract][Full Text] [Related]
37. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas. Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148 [TBL] [Abstract][Full Text] [Related]
38. Cholangiocarcinoma. Khan AS; Dageforde LA Surg Clin North Am; 2019 Apr; 99(2):315-335. PubMed ID: 30846037 [TBL] [Abstract][Full Text] [Related]
39. Detection of telomerase reverse transcriptase mRNA in biopsy specimens and bile for diagnosis of biliary tract cancers. Itoi T; Shinohara Y; Takeda K; Nakamura K; Shimizu M; Ohyashiki K; Hisatomi H; Nakano H; Moriyasu F Int J Mol Med; 2001 Mar; 7(3):281-7. PubMed ID: 11179508 [TBL] [Abstract][Full Text] [Related]
40. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Van Dyke AL; Shiels MS; Jones GS; Pfeiffer RM; Petrick JL; Beebe-Dimmer JL; Koshiol J Cancer; 2019 May; 125(9):1489-1498. PubMed ID: 30645774 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]